Descartes 08 retreatment brings lasting relief for myasthenia gravis patients

By Elena MacLeod · September 30, 2026, 2:35 AM · 3 mins read

New data from Cartesian Therapeutics show that retreatment with Descartes 08 gives myasthenia gravis patients lasting symptom relief and no new safety problems.

Five people with myasthenia gravis got a second round of Descartes-08 after their symptoms came back a year or more after the first treatment. Cartesian Therapeutics released the new results. The numbers are clear. Patients saw real drops in disease severity scores. The safety record stayed clean, even after another course.

An official SEC filing from September 29, 2026, details the retreatment group. All five had symptoms return after 12 months of follow-up from their first Descartes-08 course. Each got six weekly infusions as retreatment. At twelve months after the second course, the average drop was 6.6 points in MG-ADL and 15 points in MGC scores. Four out of five kept these gains for the full year. No one needed lymphodepleting chemotherapy or a hospital stay.

Descartes-08 retreatment was administered entirely in the outpatient setting, with no cases of cytokine release syndrome, neurotoxicity, cytopenias, or hypogammaglobulinemia reported in the cohort.

SEC/EDGAR

Safety is always a worry with cell therapy, especially for autoimmune diseases. Here, Descartes-08 held up. No new safety issues. No serious side effects. No cases of cytokine release syndrome, neurotoxicity, cytopenias, or hypogammaglobulinemia in the retreatment group. All doses were given in outpatient clinics. That matters. Most CAR-T treatments still need hospital care.

Dr. James F. Howard Jr. from the University of North Carolina School of Medicine led the Phase 2b trial. He pointed to the real-world impact. Being able to safely retreat patients and get symptoms back under control could change the outlook for people with generalized myasthenia gravis. These patients have few long-lasting options.

Cartesian Therapeutics is moving ahead. The company is testing Descartes-08 in myositis and in children with autoimmune diseases. It already holds Regenerative Medicine Advanced Therapy and Orphan Drug Designations from the FDA. The big test comes soon. Topline results from the Phase 3 AURORA trial are due in the first quarter of 2027. That could be a turning point.

Descartes-08 has received both RMAT (Regenerative Medicine Advanced Therapy) and Orphan Drug Designation from the FDA for myasthenia gravis, and Cartesian Therapeutics has secured written agreement with the FDA under the Special Protocol Assessment (SPA) process for its Phase 3 program.

SEC/EDGAR

The cell therapy field is changing fast. As covered earlier, next-generation CAR-T therapies are drawing big investment for cancer and autoimmune diseases. But few have shown the outpatient, repeatable, and lasting results now seen with Descartes-08.

No new safety problems. Clear, lasting benefit after retreatment. Cartesian Therapeutics is putting Descartes-08 at the front of the pack for CAR-T in autoimmune disease. The data raise the bar for rivals still struggling with side effects and short-lived results. If the Phase 3 trial backs this up, Descartes-08 could set a new standard for myasthenia gravis—and maybe for other autoimmune diseases too.

Topics:

Biotechnology Newsroom

Elena MacLeod

Elena MacLeod is Clinical Biotechnology Editor at GenoMethods, covering CAR-T, engineered cell therapies, gene therapy, clinical trials, cancer immunology and regulatory developments. Her evidence-first reporting focuses on trial design, patient populations, safety, efficacy, response durability and the limitations that determine how early clinical results should be interpreted.